( CAMBRIDGE Mass.--(BUSINESS WIRE)--Jun ...)Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at Molecular Insight Pharmaceuticals today announced the presentation of preclinical data on MIP-1072, a radiolabeled, small molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer at the 54th annual meeting of the Society of Nuclear Medicine (SNM) in Washington, D.C. MIP-1072 is one of two development candidates for prostate cancer diagnosis that Molecular Insight plans to advance into exploratory human studies in the first half of next year. It is designed to target prostate specific membrane antigen (PSMA), a protein highly expressed by prostate tumor cells. The presentation is one of four on the company's products and technologies to be presented at the meeting.

"Accurate diagnosis and the ability to properly assess the true extent and aggressiveness of prostate cancer are fundamental to appropriate therapeutic management of the disease," said John W. Babich, Ph.D., President and Chief Scientific Officer of Molecular Insight and an author on the study. "Treatment of prostate cancer is challenging, and the effects of treatment may substantially impact a man's quality of life for many years. Therefore, it is crucial that those faced with difficult clinical questions make the right decisions."

"We believe PSMA represents an exceptional target for the molecular imaging of prostate cancer due to its near 100% expression in the disease. Our preclinical studies suggest that MIP-1072 can identify the presence of prostate tumors specifically and non-invasively by targeting PSMA expression on prostate cancer cells. A PSMA-targeted molecular imaging pharmaceutical such as MIP-1072 may lead to improvements in the staging of prostate cancer patients and may represent a unique opportunity to risk stratify patients and monitor response to therapy," he added.

The Society of Nuclear Medicine recognized th
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
3. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
4. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
5. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference